Trial intelligence / Profile preview

MR-HYPERPOLARISATION SCANNING WITH HYPERPOLARISED PYRUVATE (13C) IN PANCREATIC CANCER PATIENTS – A FEASIBILITY STUDY

2024-517358-86-00Phase 2Authorised

Sponsor: Aarhus University
Start: Sep 2024
Modality: Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of [1-13C]pyruvate in pancreatic adenocarcinoma (PDAC), sponsored by Aarhus University. Planned start Sep 2024; status: authorised.

Drugs

[1-13C]pyruvate

Conditions

pancreatic adenocarcinoma (PDAC)

Beyond the preview

Go deeper on 2024-517358-86-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-517358-86-00.